Drug Trial Radar · NCT06741228
A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)
Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
214
Actual
Start
Dec 11, 2024
Primary completion
Jul 15, 2026
Study completion Apr 2027
Sponsor
- Lead sponsor
- Definium Therapeutics US, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 18, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Generalized Anxiety Disorder - Voyage
Conditions
- Generalized Anxiety Disorder
Interventions
PlaceboOther
A substance that is designed to have no therapeutic value
DT120Drug
A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in Hamilton Anxiety Rating Scale (HAM-A) total score at Week 12Time frame: Baseline to Week 12
Locations
34 sites in 1 country. Site status is shown where the registry gives one.
Lighthouse Psychiatry
Gilbert, Arizona
Scottsdale Research Institute
Scottsdale, Arizona
Kadima Neuropsychiatry Institute
La Jolla, California
UCSF Department of Neurology
San Francisco, California
Psychedelic Science Institute
Santa Monica, California
Mountain View
Denver, Colorado
Clinical Neuroscience Solutions Inc.
Jacksonville, Florida
Segal Trials
Lauderhill, Florida
Atlanta Center for Medical Research
Atlanta, Georgia
iResearch Atlanta
Decatur, Georgia
CenExel iResearch, LLC
Savannah, Georgia
Uptown Research Institute
Chicago, Illinois
Adams Clinical Boston
Boston, Massachusetts
Adams Clinical Watertown
Watertown, Massachusetts
Hassman Research Institute
Marlton, New Jersey
Spectrum Neuroscience and Treatment Institute
New York, New York
Adams Clinical Harlem
New York, New York
New York State Psychiatric Institute (NYSPI)
New York, New York
Adams Clinical Bronx
The Bronx, New York
Cleveland Clinic Lutheran Hospital
Cleveland, Ohio
Summit Headlands LLC
Portland, Oregon
Scranton Medical Institute
Moosic, Pennsylvania
Adams Clinical Philadelphia
Philadelphia, Pennsylvania
Coastal Carolina Research Center
North Charleston, South Carolina
Clinical Neuroscience Solutions, Inc.
Memphis, Tennessee
University of Texas at Austin
Austin, Texas
Austin Clinical Trial Partners
Austin, Texas
BioBehavioral Research of Austin
Austin, Texas
FutureSearch Trials of Dallas, LLC
Dallas, Texas
Adams Clinical Dallas
DeSoto, Texas
Cedar Clinical Research
Draper, Utah
Inner Space Research
Orem, Utah
Memory Clinic Inc.
Bennington, Vermont
Seattle Neuropsychiatric Treatment Center
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.